一周倒计时！2026药明康德全球论坛公布嘉宾名单 | Bilingual

从2000到2025年，全球生物医药产业走过了不断探索与进步的四分之一个世纪。

在这25年间，人类逐步读懂生命“天书”的篇章，精准医疗日益走向成熟；世纪之交，格列卫的问世宣告理性药物设计与靶向治疗时代的到来。与此同时，寡核苷酸、多肽、细胞与基因疗法等创新治疗模式持续涌现，持续拓展着医学的边界，也让越来越多曾被视为“无药可治”的疾病，迎来了新的治疗希望。科研机构、产业力量与资本之间的协作愈发紧密，为创新落地不断汇聚合力。

与此同时，我们也清醒地看到，新药研发仍是一条充满挑战的道路——研发周期漫长、投入巨大，可及性与可负担性仍有待提升，且仍有多种疾病尚未被完全攻克。如何让创新真正惠及更多患者，依然是摆在全球产业面前的时代命题。也正因为如此，行业协作、跨界交流与思想碰撞显得尤为重要。

诞生于2000年， 药明康德与全球创新同行，与数千位合作伙伴一道，既见证行业的跨越式进展，也陪伴产业穿越周期、稳步前行。

2026年1月13日，我们将延续14年的传统，于摩根大通医疗健康大会（J.P. Morgan Healthcare Conference）期间，在旧金山隆重举办2026药明康德全球论坛。

在这个愈发需要勇气与协作的时代，来自全球的投资人、创新者、科研专家以及行业领袖将齐聚旧金山，共同探讨新时代中的机遇与挑战。群英荟萃、星光璀璨的嘉宾阵容，将为全球医药创新者带来基于多元背景与不同视角的深度交流与前瞻洞见。

如同往年，药明康德全球论坛将继续实行申请批准制，向收到确认函的嘉宾免费开放。

在旧金山，让我们再度见证产业的力量与温度，并共同坚守那份始终不变的信念：

“让天下没有难做的药，难治的病。”

WuXi Global Forum 2026: Together, We Advance Breakthroughs for Patients

From 2000 to 2025, the global biopharmaceutical industry has undergone a quarter century of continuous exploration and progress.

Over the past 25 years, humanity has gradually learned to read the “book of life,” and precision medicine has steadily matured. At the turn of the century, the launch of Gleevec marked the beginning of an era of rational drug design and targeted therapies. Meanwhile, innovative treatment modalities such as oligonucleotides, peptides, and cell and gene therapies have continued to emerge, expanding the frontiers of medicine and offering new hope to patients with diseases once considered “untreatable.” Collaboration among research institutions, industry stakeholders, and the investment community has also grown closer, creating stronger momentum to translate innovation into real-world impact.

At the same time, we recognize that new drug development remains a highly complex and resource-intensive endeavor—characterized by long development cycles, significant investment requirements, and continuing challenges around access and affordability, while many diseases still lack effective treatment options. How to ensure that innovation benefits a broader patient population remains a key question for the global industry. As such, cross-industry collaboration, open exchange and forward-looking dialogue are more important than ever.

Founded in 2000, WuXi AppTec has advanced in step with global innovators. Together with thousands of partners worldwide, the company has witnessed the industry’s significant breakthroughs while supporting its steady progress through multiple market cycles.

On January 13, 2026, WuXi AppTec will proudly host the 14th WuXi Global Forum in San Francisco, alongside the J.P. Morgan Healthcare Conference—continuing a tradition that has united global leaders for more than a decade.

In an era that increasingly calls for courage and collaboration, investors, innovators, scientific leaders, and industry executives from around the world will gather in San Francisco to explore the opportunities and challenges of a new era.

With a distinguished lineup of world-class speakers, the Forum will bring forward-looking insights and in-depth dialogue to the global biopharmaceutical community, reflecting diverse backgrounds and perspectives across the industry.

As always,the WuXi Global Forum is complimentary and open to innovators across the global ecosystem.

Due to limited space, admission will be by approval only, and entry will be granted to confirmed guests.

In San Francisco, we will once again witness the power and purpose of our industry — and reaffirm the belief that continues to guide us:

“Every drug can be made, and every disease can be treated.”

免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。